{"name":"OptiNose AS","slug":"optinose-as","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPVEJvY3pUOUVLc3FFaGZPS3pjVF83dktUOVlnRkRsWjVXZkllcURmRGI2ZlpSYU9iZGg5RGlBeHk3Ty1Za2tzaE1ybmlFQkdYeGZmalUwVnZzSm1ibDVCSnFyYW8tZ2NvSDd5TTh1Q2pMbzd2dlNEOWh6Sy1RcEJpTmgtYTBzLTh1M2JuWDEwb3dOQzhyZHlzVk1qSTM0MnNQeHJUTldIWQ?oc=5","date":"2025-05-23","type":"pipeline","source":"The Business Journals","summary":"Optinose CEO and other top executives exit after company's acquisition by Paratek - The Business Journals","headline":"Optinose CEO and other top executives exit after company's acquisition by Paratek","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPR0dRbFYtMDF6UDNLVG92OXplUWN0dFcyUy0wdExYSERVa3JheTFnVC14eWw0bjM1aDVSM293cmFtY0RjOWVPbmJ1SUVDVmtfaGJ5cVRfOEZGNkJ0ZER6MFFBbXZIb1RReGRlQW1VZlpDZDItVjNLNEV6ZC03cXBIWlBR?oc=5","date":"2025-05-22","type":"pipeline","source":"Pharmaceutical Technology","summary":"Paratek expands commercial portfolio with acquisition of Optinose - Pharmaceutical Technology","headline":"Paratek expands commercial portfolio with acquisition of Optinose","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQZWdicVoyNTFjRW9DemlVTmNUUVRPTllJVmhoYUZXdm40Y1hKekU4X1gyaTVEUThCMUJqU0xrWFZBRzR5SHAtSHJRVkdValhSdWtFTzdGODctVjVVQzJfUUw3NE02WllSUE5PNXFZeF9oVEJvUjl2d084Y2IyYi1pNWtyVUFTNWVDb2w1c3I3WWdCazRiMmY1cmdSc0EyeVR5NWdfQzREbkhjQjhobC1pdEhKcUI3TUdpcVU0TENvVDRDRDVKbjR3NnYxRjd0bkpzbGtfb0J6Qzk5Zw?oc=5","date":"2025-05-22","type":"pipeline","source":"Akin","summary":"Akin Advised Pharmakon in its Debt Financing for Optinose’s Sale to Paratek Pharmaceuticals - Akin","headline":"Akin Advised Pharmakon in its Debt Financing for Optinose’s Sale to Paratek Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9TcHFJcHcyLVdEV1lqdGhSVndFQ1ltVFEzSm1mdW94c2VTYWUxUXBvbi1BZ1FOYWVzem54WENQcWctU0dOSFVjSXZ5VFRGUTgxYkxQRnM4QnVYdjUzd0g3YUtWV3M2Vm96MlpSenlBYnc0elU?oc=5","date":"2025-04-15","type":"deal","source":"BUCKSCO.Today","summary":"After Fielding Multiple Offers, Yardley-Based Optinose Secures Potential $330M Deal With Paratek - BUCKSCO.Today","headline":"After Fielding Multiple Offers, Yardley-Based Optinose Secures Potential $330M Deal With Paratek","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQUnFSbjVZdnhyMmlYNG1xcl83YVkyazZxcEVRMnZ2QjRIT2M2WkJPb0dRX2ZHc19Wcl9EYmRHNV90b3pVc2d2eTdXVi1Od0x6YmRUUzZuQlVpQXBKcFNUVGxyeEJyNHpCNzRISi1DMVYzR3AzTF90YTNRX0VuN29SdFRvWQ?oc=5","date":"2025-03-20","type":"deal","source":"The Pharma Letter","summary":"Paratek to buy Optinose for up to $330 million - The Pharma Letter","headline":"Paratek to buy Optinose for up to $330 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9VSDBfYXA0cnU0Ui1MRld1VEx4WktBVEl0elNMVzlYN3ZSWTFKZVBhVGFZY2pBZGkxU1F2bXpWaVdHdWZtSXU1bFg4QzhwTzJyd0w0?oc=5","date":"2025-03-20","type":"pipeline","source":"FirstWord Pharma","summary":"Paratek adds chronic rhinosinusitis drug to portfolio with $330M Optinose acquisition - FirstWord Pharma","headline":"Paratek adds chronic rhinosinusitis drug to portfolio with $330M Optinose acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQd18xV25Wbi1YOWdlTVJLdVF4eTJjNUpsaXhLN01Ga3AxMWdWOFk4bmpYQnhvbTgyZ0RndHFyeWtjSkljYUlWMFNveFZoS2ppUHMtMWFXQUNpZlpaSlZMYUxpVlp4RU04WGdpdXlCMGQ2eDJDWWZOdnc2VHBQdG5KLXlDWkJSZ3lIOE5CemFsRG5XNDVnRGtjYXRrWQ?oc=5","date":"2025-03-20","type":"deal","source":"BioSpace","summary":"Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M - BioSpace","headline":"Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQYzJnMjQ2QXpQbVY5MlZ4d3lqMWRKX0JwNVJ1andjWEdZOUFTQUZSTkEtOWh2OWtzOEh0TDkxUEVPcDBYeUo0TEQ5QXpTUEcwVlVfc0stc3JwTGl2bks4NEg2UEVxUVdfS0p6STliVGJfQzdYcFN3ajFVOWg0M0ZEZUJ5Vko3NmEwbXZ1dXB0WQ?oc=5","date":"2025-03-20","type":"deal","source":"World Pharmaceutical Frontiers","summary":"Paratek Pharmaceuticals to acquire Optinose for up to $330m - World Pharmaceutical Frontiers","headline":"Paratek Pharmaceuticals to acquire Optinose for up to $330m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOOW9vZFZSRk1KdWR2dkdGeFBZa2pBR2VpWUp5VWJISUhYWVV6MmxoVDFCeDhVVXp1bndWQktJZmt0dUpKYkNscHA5eXdXU1o5bkZwT1pMbk81TWNYbzlXbklzbkRxaFNpVUFOMzhSalRmemhiZkN1dGgxYnNNaXcwcUJ3dzRzU3NVUVlIY3Nfd1VfLVU2bGVwd1N3NEg?oc=5","date":"2022-12-15","type":"pipeline","source":"citybiz","summary":"Optinose Appoints Paul Spence as Chief Commercial Officer - citybiz","headline":"Optinose Appoints Paul Spence as Chief Commercial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOVEk2ODU4R1pGOGJ6TU82YkRvOE9vZ0tMcmJCa2JDU3hFUkU1cU91ZXJab0RqYUJSajZHcEZMbFVYVzFjNEd2dk90Y0Q0ejk2eUsxZ1FZcWVQTUdJeGhVOXk0WW9rRkhVRXV0elBLcXNxSjFKRGJHS3Zzdml4SDdNQUVYWVJDRUlpeFhVcXdnYnVCRmZLSEFHZUpPazExRmtUWlFnaWIzQkY2YlB4VmpNbmt6b1duSG80dUxDNDQ4dWdsdGZv?oc=5","date":"2022-03-08","type":"trial","source":"Fierce Pharma","summary":"And, exhale: Relief for Optinose as delivery system hits primary endpoints in chronic sinusitis phase 3 - Fierce Pharma","headline":"And, exhale: Relief for Optinose as delivery system hits primary endpoints in chronic sinusitis phase 3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPMTZMR3dJdWp2OHVEOWdibEw1cGlGTjJ2ZmMxV2J2bTNhUlo4UnVOS3lXU2Z2LWx4LWNRWHlJTnJHOTNOTko4VzExQUt0bXo4dlJsRFlSdkY0MUs0dDNiR2RWdTcycUJtVUlUc29aamVReVNWckZLb2I0Nm9ObGp5WFVqN0E0Rl85SG0tU0xDM1VJZk9kRm53dTlXeHZRUTU5eWxSTHM2Wl9mbnBxZ0FON2hzeGM0Y3pzYnFxWkdTR0YtRGl0dHZIbWt5bWp0Z1haWGtkdTVsRjJTeEZ1dXFlSk55Q0dVelN0?oc=5","date":"2018-12-11","type":"deal","source":"PR Newswire","summary":"Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA® Xsail® - PR Newswire","headline":"Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA® Xsail®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNVUJXb2JjcTNZQ2p6b0RSd2gtODhyWXo5VHR3dkc5UlpqLWhBcTM1aG9QeTEyeUtIRjY5Q1BtTW1zUml1SGxWakNpV19yQVVPeVZUYUxqNXZqcGVuME5wc3o5NjN3R2xpbjZqY2dDeFhmLXpjdlc2WTJjMEJpbjI0SDVEUEZnZHJfdHlYMmM4SGxDbUNBZ1pEN2tpN2tMVU9JRjQ4X25UQVJPZHpkN3Z2aUNjQkx0Zw?oc=5","date":"2016-11-02","type":"pipeline","source":"Healthcare Packaging","summary":"OptiNose’s Inventive Nasal Spray Device - Healthcare Packaging","headline":"OptiNose’s Inventive Nasal Spray Device","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}